Targeted DPPC/DMPG surface-modified voriconazole lipid nanoparticles control invasive pulmonary aspergillosis in immunocompromised population: in-vitro and in-vivo assessment

Fayyaz, Heba A.; EL-Massik, Magda A.; Bahey-El-Din, Mohammed; Abdel-Bary, Amany; Abdallah, Ossama Y.; Eltaher, Hoda M.

Abstract

Invasive pulmonary aspergillosis (IPA) is the most devastating Aspergillus-related lung disease. Voriconazole (VRZ) is the first-line treatment against IPA. Despite availability in oral and parenteral dosage forms, risks of systemic toxicity dictate alternative pulmonary administration. Inspired by natural lung surfactants, dipalmitoylphosphatidylcholine/dimyristoylphosphatidylglycerol (DPPC/DMPG) surface-modified lipid nanoparticles (LNPs) were scrutinized for pulmonary administration. DPPC/DMPG-VRZ-LNPs prepared using ultrasonication/thin film hydration were investigated for colloidal properties over 3-month shelf storage. They were stable with a slight change in entrapment efficiency. They provided a sustained VRZ release over 24 h, with a rapid initial release. In vitro aerosolization indicated higher percentages of VRZ deposited on stages corresponding to secondary bronchi and alveolar ducts. Moreover, intrapulmonary administration maintained high lung VRZ concentration (27 ± 1.14 µg/g) after 6 h. A preclinical study using a cyclophosphamide-induced neutropenic rat model demonstrated a 3-fold reduction in BALF-Galactomannan down to 0.515 ± 0.22 µg/L confirming DPPC/DMPG-VRZ-LNPs potential in hyphal growth inhibition. Histopathological examination of infected/nontreated lung sections exhibited dense fungal load inside alveoli and blood vessels indicating massive tissue and angio-invasiveness. Nevertheless, DPPC/DMPG-VRZ-LNPs-treated animals displayed minimal hyphae with no signs of invasiveness. The developed bioinspired nanoparticles serve as prospective bioactive nanocarrier candidates for pulmonary administration of VRZ in the management of IPA.

Citation

Fayyaz, H. A., EL-Massik, M. A., Bahey-El-Din, M., Abdel-Bary, A., Abdallah, O. Y., & Eltaher, H. M. (2024). Targeted DPPC/DMPG surface-modified voriconazole lipid nanoparticles control invasive pulmonary aspergillosis in immunocompromised population: in-vitro and in-vivo assessment. International Journal of Pharmaceutics, 649, Article 123663. https://doi.org/10.1016/j.ijpharm.2023.123663

• Journal Article Type: Article
• Acceptance Date: Nov 30, 2023
• Online Publication Date: Dec 11, 2023
• Publication Date: Jan 5, 2024
• Deposit Date: Dec 12, 2023
• Publicly Available Date: Dec 13, 2023
• Journal: International Journal of Pharmaceutics
• Print ISSN: 0378-5173
• Electronic ISSN: 1873-3476
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 649
• Article Number: 123663
• DOI: https://doi.org/10.1016/j.ijpharm.2023.123663
• Keywords: Dipalmitoylphosphatidylcholine; Dimyristoylphosphatidylglycerol; Prophylaxis; Voriconazole; Invasive Pulmonary Aspergillosis; Immunocompromised; Targeted Delivery
• Public URL: https://nottingham-repository.worktribe.com/output/28152247
• Additional Information: This article is maintained by: Elsevier; Article Title: Targeted DPPC/DMPG surface-modified voriconazole lipid nanoparticles control invasive pulmonary aspergillosis in immunocompromised population: in-vitro and in-vivo assessment; Journal Title: International Journal of Pharmaceutics; CrossRef DOI link to publisher maintained version: https://doi.org/10.1016/j.ijpharm.2023.123663; Content Type: article; Copyright: © 2023 The Author(s). Published by Elsevier B.V.